(Q37679949)

21 August 2017

1 reference

title

Enhancement of the efficacy of therapeutic proteins by formulation with PEGylated liposomes; a case of FVIII, FVIIa and G-CSF. (English)

1 reference

21 August 2017

Rivka Yatuv

1

1 reference

21 August 2017

Micah Robinson

series ordinal

2

1 reference

21 August 2017

Inbal Dayan

series ordinal

3

1 reference

21 August 2017

Moshe Baru

series ordinal

4

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 February 2010

1 reference

Expert Opinion on Drug Delivery

21 August 2017

published in

1 reference

21 August 2017

volume

7

1 reference

21 August 2017

issue

2

1 reference

21 August 2017

page(s)

187-201

1 reference

Strategies to improve oral drug bioavailability

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Emerging strategies for the transdermal delivery of peptide and protein drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Formulations for delivery of therapeutic proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Advances in PEGylation of important biotech molecules: delivery aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Pegylation: a novel process for modifying pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Effect of pegylation on pharmaceuticals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Pharmacokinetic and biodistribution properties of poly(ethylene glycol)–protein conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Immunogenicity of protein therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Chondroosseous dysplasia in severe combined immunodeficiency due to adenosine deaminase deficiency (chondroosseous dysplasia in ADA deficiency scid)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Pegaspargase: a review of clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Evaluation of the safety and pharmacokinetics of a fast-acting recombinant FVIIa analogue, NN1731, in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Chemistry for peptide and protein PEGylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Insulin analogues: an example of applied medical science

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Development and characterization of novel erythropoiesis stimulating protein (NESP)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of hemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Factor VIIa analogue (V158D/E296V/M298Q-FVIIa) normalises clot formation in whole blood from patients with severe haemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Effect of recombinant factor VIIa variant (NN1731) on platelet function, clot structure and force onset time in whole blood from healthy volunteers and haemophilia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Development, characterization, and evaluation of a fusion protein of a novel glucagon-like peptide-1 (GLP-1) analog and human serum albumin in Pichia pastoris

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Elimination of the free sulfhydryl group in the human serum albumin (HSA) moiety of human interferon-alpha2b and HSA fusion protein increases its stability against mechanical and thermal stresses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Effects of genetic fusion of factor IX to albumin on in vivo clearance in mice and rabbits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Nanoparticle-based targeted drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Bacterial ghosts as a novel advanced targeting system for drug and DNA delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Erythrocyte-based drug delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Concept and clinical evaluation of carrier-mediated anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Liposome-based drug delivery in breast cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

New-concept chemotherapy by nanoparticles of biodegradable polymers: where are we now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

The use of PEGylated liposomes to prolong circulation lifetimes of tissue plasminogen activator.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Delivery of cytokines by liposomes: hematopoietic and immunomodulatory activity of interleukin-2 encapsulated in conventional liposomes and in long-circulating liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Enzymes inside lipid vesicles: preparation, reactivity and applications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Protein encapsulation in liposomes: efficiency depends on interactions between protein and phospholipid bilayer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Preparation of liposomes containing factor VIII for oral treatment of haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Ultrasound-facilitated thrombolysis using tissue-plasminogen activator-loaded echogenic liposomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Entrapment of proteins in phosphatidylcholine vesicles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Enhancement of haemostatic efficacy of plasma-derived FVIII by formulation with PEGylated liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Enhancement of factor VIIa haemostatic efficacy by formulation with PEGylated liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Binding of proteins to PEGylated liposomes and improvement of G-CSF efficacy in mobilization of hematopoietic stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Synovium in haemophilic arthropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Development of improved factor VIII molecules and new gene transfer approaches for hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Strategies towards a longer acting factor VIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

An engineered interdomain disulfide bond stabilizes human blood coagulation factor VIIIa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Intrinsic stability and functional properties of disulfide bond-stabilized coagulation factor VIIIa variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Infusion rates of recombinant FVIII-FS with PEGylated liposomes in haemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Current opinion on inhibitor treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Pharmacokinetics and pharmacodynamics of recombinant factor VIIa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Use of albumin fusion technology to prolong the half-life of recombinant factor VIIa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

G-CSF: a key regulator of neutrophil production, but that's not all!

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

The use of mobilized peripheral blood stem cells from normal donors for allografting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Transplantation of hematopoietic stem cells from the peripheral blood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Liposomes and blood cells: a flow cytometric study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Blood coagulation and its regulation by anticoagulant pathways: genetic pathogenesis of bleeding and thrombotic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Mechanism of action of factor VIIa in the treatment of coagulopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

The leak stops here: platelets as delivery vehicles for coagulation factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903463846

10.1517/17425240903463846

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference